Turquoise's public comment on CMS-9882-NC
Turquoise Health is in full support of the Departments' commitment to broadening price transparency requirements to include prescription drugs. Transparency is ultimately about reducing the financial complexity of healthcare and creating an ecosystem that allows patients to shop for care in advance. Transparent reporting of prescription drug rates is a critical step in building infrastructure that enables patients to receive a comprehensive cost of care before an appointment occurs.
Related resources
Learn, listen, and watch the latest on price transparency.
Turquoise's public comment on CMS-1834-P
Turquoise Health's public comment on CMS-1834-P supporting comprehensive hospital MRF standards, seeking clarification on new percentile fields, and providing recommendations on EDI 835 ERA transaction data utility. Read our full analysis.
2025 drug reimbursement trends report
Turquoise Health and ZS's 2025 drug reimbursement trends report analyzes millions of hospital and payer-reported drug rates across 17 products and 4 therapeutic areas revealing how payer-provider dynamics drive reimbursement from 3× to 10× ASP. Explore the data.